ASH 2021 Conference Coverage on VuMedi

 

Lymphoma
05:05

ASH 2021 Conference Coverage on VuMedi

A Multi-Institution Analysis of Relapsed Lymphoma Occurring During Pregnancy Including Pharmacokinetics With Antenatal CPI Therapy

FEATURING Faheem Farooq
  • 15 views
  • April 13, 2022
07:23

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Five-Year Follow-Up of Keynote-087: Pembrolizumab Monotherapy in R/R cHL

FEATURING Alex Herrera
  • 281 views
  • March 24, 2022
  • 1
24:07

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights: CAR-T as 2L Therapy in R/R Aggressive NHL

FEATURING Nausheen Ahmed
  • 91 views
  • January 26, 2022
12:04

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Safety and Efficacy of CD37-Targeting Naratuximab Emtansine + Rituximab in DLBCL and Other NHLs: A Phase 2 Study

FEATURING Moshe Y. Levy
  • 121 views
  • January 4, 2022
  • 1
14:15

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Outcomes & Treatment Patterns in Pts With Aggressive B-Cell Lymphoma After Failure of Anti-CD19 CAR-T

FEATURING Joanna Zurko
  • 221 views
  • December 25, 2021
  • 1
10:55

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on a Phase II Study of OB-VEN in Patients With HTB-FL as 1L Therapy

FEATURING Craig Portell
  • 76 views
  • December 23, 2021
10:52

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Managing R/R DLBCL: Surveying Treatment Landscape

FEATURING Andre Goy
  • 24 views
  • December 23, 2021
09:47

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on Brexucabtagene Autoleucel for R/R MCL: Real-World Experience From the US Lymphoma CAR T Consortium

FEATURING Yucai Wang
  • 23 views
  • December 22, 2021
06:00

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Concurrent Pembrolizumab With AVD for Untreated Classical Hodgkin Lymphoma

FEATURING Ryan C. Lynch
  • 82 views
  • December 20, 2021
17:50

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Allogeneic CAR-T PBCAR0191 With Intensified Lymphodepletion in R/R B-Cell Malignancies

FEATURING Bijal Shah
  • 66 views
  • December 20, 2021
10:59

ASH 2021 Conference Coverage on VuMedi

ASH 2021: Glofitamab + R-CHOP Induces High Response Rates With Minimal CRS in R/R NHL and 1L DLBCL

FEATURING Nilanjan Ghosh
  • 157 views
  • December 20, 2021
  • 1
09:46

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Frontline Treatment With Pembrolizumab Followed by AVD Chemo for cHL: Updated Results and Correlative Analysis

FEATURING Pamela Allen
  • 243 views
  • December 17, 2021
08:18

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Umbralisib + Ublituximab Combo in R/R MZL: Results From the Phase 2 UNITY-NHL Trial

FEATURING Julio Chavez
  • 63 views
  • December 16, 2021
10:20

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Real-World Case Studies in ctDNA

FEATURING Piers Blombery
  • 81 views
  • December 16, 2021
06:32

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on CD30-Directed CAR T-Cells for Pediatric Patients With Hodgkin/Non-Hodgkin Lymphoma

FEATURING George Hucks
  • 43 views
  • December 15, 2021